<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Jaguar Animal Health Inc — News on 6ix</title>
<link>https://6ix.com/company/jaguar-animal-health-inc</link>
<description>Latest news and press releases for Jaguar Animal Health Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/jaguar-animal-health-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835877a78dffbe2df0fe627.webp</url>
<title>Jaguar Animal Health Inc</title>
<link>https://6ix.com/company/jaguar-animal-health-inc</link>
</image>
<item>
<title>Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-announces-statistically-significant-results-from-effectiveness-trial-of-crofelemer-fda-approved-canalevia-ca1-for-treatment-of-chemotherapy-induced-diarrhea-in-dogs</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-announces-statistically-significant-results-from-effectiveness-trial-of-crofelemer-fda-approved-canalevia-ca1-for-treatment-of-chemotherapy-induced-diarrhea-in-dogs</guid>
<pubDate>Wed, 29 Apr 2026 12:30:00 GMT</pubDate>
<description>Company Advances Towards Full FDA Approval of Crofelemer for Chemotherapy-Induced Diarrhea SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2026 /Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced topline results from the completion of its ...</description>
</item>
<item>
<title>Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-announces-acceptance-of-two-late-breaking-abstracts-for-liquid-oral-crofelemer-treatment-of-intestinal-failure-in-pediatric-patients-at-the-european-society-for-pediatric-gastroenterology-hepatology-and-nutrition-espghan</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-announces-acceptance-of-two-late-breaking-abstracts-for-liquid-oral-crofelemer-treatment-of-intestinal-failure-in-pediatric-patients-at-the-european-society-for-pediatric-gastroenterology-hepatology-and-nutrition-espghan</guid>
<pubDate>Fri, 24 Apr 2026 04:00:00 GMT</pubDate>
<description>Intestinal Failure (IF) occurs in patients with an ultrarare congenital enteropathy due to microvillus inclusion disease (MVID) and/or short bowel syndrome</description>
</item>
<item>
<title>Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-reports-approval-of-all-proposals-at-april-2026-special-meeting-of-stockholders-1</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-reports-approval-of-all-proposals-at-april-2026-special-meeting-of-stockholders-1</guid>
<pubDate>Mon, 20 Apr 2026 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO, CA / ACCESS Newswire / April 20, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the</description>
</item>
<item>
<title>Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-completes-effectiveness-trial-to-support-fda-approved-crofelemer-for-treatment-of-chemotherapy-induced-diarrhea-cid-in-dogs</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-completes-effectiveness-trial-to-support-fda-approved-crofelemer-for-treatment-of-chemotherapy-induced-diarrhea-cid-in-dogs</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea (CTD) in</description>
</item>
<item>
<title>Jaguar Health Reports 2025 Financials</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-reports-2025-financials</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-reports-2025-financials</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Net revenue increase of 5% in Q4 2025 vs. Q3 2025Jaguar received an up-front payment of $16Mof non-dilutive capital in January 2026 upon entering U.S. license</description>
</item>
<item>
<title>Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-family-company-napo-pharmaceuticals-co-sponsoring-pediatric-gastroenterology-conference-elite-ped-gi-congress-29</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-family-company-napo-pharmaceuticals-co-sponsoring-pediatric-gastroenterology-conference-elite-ped-gi-congress-29</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal failure (IF) indications; all patients</description>
</item>
<item>
<title>FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/fda-feedback-supports-extension-phase-for-jaguar-healths-clinical-trial-of-crofelemer-for-treatment-of-microvillus-inclusion-disease-mvid</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/fda-feedback-supports-extension-phase-for-jaguar-healths-clinical-trial-of-crofelemer-for-treatment-of-microvillus-inclusion-disease-mvid</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>MVID has a lethal natural history requiring life-sustaining parenteral support (PS), which includes total parenteral nutrition (TPN), which is associated with</description>
</item>
<item>
<title>Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/magdalena-biosciences-a-joint-venture-between-jaguar-health-and-filament-health-initiates-preclinical-study-of-coca-for-appetite-suppression</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/magdalena-biosciences-a-joint-venture-between-jaguar-health-and-filament-health-initiates-preclinical-study-of-coca-for-appetite-suppression</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management SAN FRANCISCO, CA / ACCESS Newswire / March 16,</description>
</item>
<item>
<title>Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-presenting-march-12-at-the-life-sciences-virtual-investor-forum-to-provide-updates-on-near-term-catalysts-17</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-presenting-march-12-at-the-life-sciences-virtual-investor-forum-to-provide-updates-on-near-term-catalysts-17</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and</description>
</item>
<item>
<title>Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-strengthens-companys-balance-sheet-by-restructuring-and-reducing-royalty-and-debt-obligations-and-extinguishing-warrants-1</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-strengthens-companys-balance-sheet-by-restructuring-and-reducing-royalty-and-debt-obligations-and-extinguishing-warrants-1</guid>
<pubDate>Mon, 09 Mar 2026 13:00:00 GMT</pubDate>
<description>Strengthening balance sheet and capitalization is a key Jaguar priority Company continues its sharp, strategic focus on global development program for crofelemer for rare-disease intestinal failure indications SAN FRANCISCO, CA / ACCESS Newswire / ...</description>
</item>
<item>
<title>Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants </title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-strengthens-companys-balance-sheet-by-restructuring-and-reducing-royalty-and-debt-obligations-and-extinguishing-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-strengthens-companys-balance-sheet-by-restructuring-and-reducing-royalty-and-debt-obligations-and-extinguishing-warrants</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Strengthening balance sheet and capitalization is a key Jaguar priorityCompany continues its sharp, strategic focus on global development program for</description>
</item>
<item>
<title>Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-secures-an-additional-dollar3-million-payment-from-future-pak-for-mytesi-and-canalevia-ca1</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-secures-an-additional-dollar3-million-payment-from-future-pak-for-mytesi-and-canalevia-ca1</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>As announced, Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for</description>
</item>
<item>
<title>Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/reminder-today-march-2-2026-is-the-record-date-for-jaguar-healths-special-one-time-stock-dividend</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/reminder-today-march-2-2026-is-the-record-date-for-jaguar-healths-special-one-time-stock-dividend</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt SAN FRANCISCO, CALIFORNIA / ACCESS</description>
</item>
<item>
<title>Jaguar Health Announces a Special One-time Stock Dividend</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-announces-a-special-one-time-stock-dividend</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-announces-a-special-one-time-stock-dividend</guid>
<pubDate>Wed, 18 Feb 2026 14:00:00 GMT</pubDate>
<description>Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2026 /Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced ...</description>
</item>
<item>
<title>Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-highlights-sharp-strategic-140000079</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-highlights-sharp-strategic-140000079</guid>
<pubDate>Thu, 22 Jan 2026 14:00:00 GMT</pubDate>
<description>Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi® and Canalevia®-CA1, which has the potential to provide Jaguar up to an additional $22M with milestones and other potential ...</description>
</item>
<item>
<title>Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-presenting-january-15-140000701</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-presenting-january-15-140000701</guid>
<pubDate>Wed, 14 Jan 2026 14:00:00 GMT</pubDate>
<description>SAN FRANCISCO, CA / ACCESS Newswire / January 14, 2026 /Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, January 15, 2026 at the Lytham Partners Healthcare ...</description>
</item>
<item>
<title>Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-enters-u-license-140000985</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-enters-u-license-140000985</guid>
<pubDate>Mon, 12 Jan 2026 14:00:00 GMT</pubDate>
<description>$18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing conditions) Up to additional $20M in milestone and other future payments Future Pak becomes exclusive U.S. marketer for Mytesi® and Canalevia®-CA1 ...</description>
</item>
<item>
<title>Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/article-groundbreaking-results-study-jaguar-140000947</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/article-groundbreaking-results-study-jaguar-140000947</guid>
<pubDate>Tue, 06 Jan 2026 14:00:00 GMT</pubDate>
<description>Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure Associated with significant toxicities to patients, PS has ...</description>
</item>
<item>
<title>Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-awarded-240-000-140000417</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-awarded-240-000-140000417</guid>
<pubDate>Fri, 02 Jan 2026 14:00:00 GMT</pubDate>
<description>SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 /Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it received notice from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) on January 1, 2026 ...</description>
</item>
<item>
<title>Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)</title>
<link>https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-announces-abstract-submission-140000592</link>
<guid isPermaLink="true">https://6ix.com/company/jaguar-animal-health-inc/news/jaguar-health-announces-abstract-submission-140000592</guid>
<pubDate>Mon, 15 Dec 2025 14:00:00 GMT</pubDate>
<description>SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in October 2025 with the FDA in support of a possible expedited ...</description>
</item>
</channel>
</rss>